Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the first quarter of 2024.
- Rigel Pharmaceuticals reported earnings per share of -5 cents. This was below the analyst estimate for EPS of -3 cents.
- The company reported revenue of $29.53 million.
- This was 5.58% worse than the analyst estimate for revenue of $31.28 million.